FOSUN PHARMA

上 海 復 星 醫 藥（集 團）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

([illegible])

(Stock Code: 02196)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

[illegible]

FINANCIAL HIGHLIGHTS

	2023 *RMB*	[illegible] *RMB* [illegible]
Operating results		
[illegible]	41,249	[illegible]
[illegible]	19,653	[illegible]
[illegible]	1,100	[illegible]
[illegible]	7,720	[illegible]
[illegible]	3,277	[illegible]
[illegible]	2,399	[illegible]
Profitability		
[illegible]	47.64%	[illegible]
[illegible]	7.05%	[illegible]
Earnings per share (RMB Yuan)		
[illegible]	0.90	[illegible]
[illegible]	0.90	[illegible]
Assets		
[illegible]	113,431	[illegible]
[illegible]	45,646	[illegible]
[illegible]	56,853	[illegible]

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the year ended 31 December 2023

	Notes	2023 *RMB'000*	[illegible] *RMB'000*
REVENUE	3	**41,248,505**	[illegible]
[illegible]		**(21,595,309)**	[illegible]
[illegible]		**19,653,196**	[illegible]
[illegible]	4	**524,980**	[illegible]
[illegible]		**(9,712,237)**	[illegible]
[illegible]		**(4,495,128)**	[illegible]
[illegible]		**(131,927)**	[illegible]
[illegible]		**(4,346,045)**	[illegible]
[illegible]	6	**1,392,007**	[illegible]
[illegible]		**(831,601)**	[illegible]
[illegible]		**363,645**	[illegible]
[illegible]	7	**(1,324,831)**	[illegible]
[illegible]		**(202,030)**	[illegible]
[illegible]		**2,386,879**	[illegible]
PROFIT BEFORE TAX	5	**3,276,908**	[illegible]
[illegible]	8	**(369,504)**	[illegible]
PROFIT FOR THE YEAR		**2,907,404**	[illegible]
[illegible]			
[illegible]		**2,398,606**	[illegible]
[illegible]		**508,798**	[illegible]
		2,907,404	[illegible]
[illegible]	10		
[illegible]		**RMB0.90**	[illegible]
[illegible]		**RMB0.90**	[illegible]

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

[illegible] 31 D[illegible]r 2023

	2023	[illegible]
	RMB'000	*RMB'000*
PROFIT FOR THE YEAR	**2,907,404**	[illegible]
OTHER COMPREHENSIVE INCOME		
[illegible]		

	2023 *RMB'000*	[illegible] *RMB'000*
NON-CURRENT LIABILITIES		
[illegible]	**13,504,923**	[illegible]
[illegible]	**2,049,589**	[illegible]
[illegible]	**3,445,191**	[illegible]
[illegible]	**319,785**	[illegible]
[illegible]	**639,399**	[illegible]
[illegible]	**3,136,874**	[illegible]
[illegible]	**23,095,761**	[illegible]
[illegible]	**56,577,885**	[illegible]
EQUITY		
Equity attributable to owners of the parent		
[illegible]	**2,672,399**	[illegible]
[illegible]	**(41,928)**	[illegible]
[illegible]	**43,015,915**	[illegible]
	45,646,386	[illegible]
Non-controlling interests	**10,931,499**	[illegible]
[illegible]	**56,577,885**	[illegible]

1.1 BASIS OF PREPARATION

[illegible] **"HKFRSs"** [illegible] **"HKASs"** [illegible] **"HKICPA"** [illegible] **"RMB"** [illegible]

Basis of consolidation

[illegible] **"Group"** [illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

1.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

1.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Year ended 31 December 2023

	Pharma-ceutical manufacturing *RMB'000*	Medical devices and medical diagnosis *RMB'000*	Healthcare Service *RMB'000*	Pharma-ceutical distribution and retail *RMB'000*	Others *RMB'000*	Eliminations *RMB'000*	Total *RMB'000*
[illegible]	30,080,246	4,386,495	6,667,137	—	114,627	—	41,248,505
[illegible]	470,731	54,063	42,866	—	35,726	(603,386)	—
[illegible]	30,550,977	4,440,558	6,710,003	—	150,353	(603,386)	41,248,505
[illegible]	2,133,620	(126,443)	(200,661)	—	(80,398)	(119,758)	1,606,360
[illegible]	342,065	56,167	49,453	—	49,415	—	497,100
[illegible]	329,170	56	23,039	—	149,667	—	501,932
[illegible]	235,169	30,611	24,260	—	2,615	(23,896)	268,759
[illegible]	(254,032)	(34,398)	(245,598)	—	(44,186)	133,272	(444,942)
[illegible]	(288,780)	(93,932)	(65,354)	—	(1,002)	1,173	(447,895)
[illegible]							
[illegible]	(209,238)	—	(1,376)	—	8,584	—	(202,030)
[illegible]	27,365	128,527	1,427	2,242,195	(12,635)	—	2,386,879
[illegible]							(889,255)
[illegible]	2,315,339	(39,412)	(414,810)	2,242,195	72,060	(9,209)	3,276,908
[illegible]	(341,571)	6,666	(25,005)	—	(6,189)	—	(366,099)
[illegible]							(3,405)
[illegible]	1,973,768	(32,746)	(439,815)	2,242,195	65,871	(9,209)	2,907,404
[illegible]	60,228,777	10,328,867	15,575,622	18,972,525	5,096,173	(2,997,488)	107,204,476
[illegible]							
[illegible]	67,249	—	—	—	11,661	—	78,910
[illegible]	505,797	1,483,895	688,591	18,972,525	2,151,305	—	23,802,113
[illegible]							6,226,751
[illegible]							113,431,227
[illegible]	24,081,873	2,672,929	7,609,566	—	2,077,696	(13,666,779)	22,775,285
[illegible]							34,078,057
[illegible]							56,853,342
[illegible]							
[illegible]	2,186,643	369,461	532,164	—	114,485	—	3,202,753
[illegible]	224,224	82,804	53,055	—	—	—	360,083
[illegible]							(8,414)
[illegible]	4,470,575	551,519	602,539	—	133,195	—	5,757,828

[illegible]

[illegible]

Year ended 31 December 2022

[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	—	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]	—
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	—	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	—	[illegible]	—	[illegible]	—	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]
[illegible]							[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	—	[illegible]
[illegible]							[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	—	—	—	[illegible]	—	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]
[illegible]							[illegible]
[illegible]							[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]	[illegible]
[illegible]							[illegible]
[illegible]							[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	—	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	—	[illegible]
[illegible]							[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	—	[illegible]

[illegible]

[illegible]

Revenue from contracts with customers

(i) *D a e aed e e e a*

For the year ended 31 December 2023

Segments	Pharmaceutical manufacturing *RMB'000*	Medical devices and medical diagnosis *RMB'000*	Healthcare Service *RMB'000*	Pharmaceutical distribution and retail *RMB'000*	Others *RMB'000*	Total *RMB'000*
Type of goods or services						
[illegible]	28,532,071	4,245,408	686,595	—	32,949	33,497,023
[illegible]	1,517,980	127,270	5,976,603	—	33,450	7,655,303
[illegible]	22,320	11,258	—	—	—	33,578
[illegible]	30,072,371	4,383,936	6,663,198	—	66,399	41,185,904
Geographical markets						
[illegible]	22,629,786	1,466,935	6,654,040	—	64,528	30,815,289
[illegible]	7,442,585	2,917,001	9,158	—	1,871	10,370,615
[illegible]	30,072,371	4,383,936	6,663,198	—	66,399	41,185,904
[illegible]	28,554,391	4,256,666	686,595	—	32,949	33,530,601
[illegible]	1,205,727	34,162	5,976,603	—	33,450	7,249,942
[illegible]	312,253	93,108	—	—	—	405,361
[illegible]	30,072,371	4,383,936	6,663,198	—	66,399	41,185,904

For the year ended 31 December 2022

[illegible]	[illegible] *RMB'000*	[illegible] *RMB'000*	[illegible] *RMB'000*	[illegible] *RMB'000*	[illegible] *RMB'000*	[illegible] *RMB'000*
Type of goods or services						
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	—	—	—	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
Geographical markets						
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]						
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	—	—	—	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	—	[illegible]	[illegible]

[illegible]

	2023 *RMB'000*	[illegible] *RMB'000*
[illegible]		
[illegible]	**1,493,312**	[illegible]
[illegible]	**51,450**	[illegible]
	1,544,762	[illegible]

(ii) ***Pe a ce b a***

[illegible]

S

[illegible]

R r r K

— [illegible]

— [illegible]

[illegible]

	2023 ***RMB'000***	[illegible] *RMB'000*
[illegible]		
[illegible]	**1,200,496**	[illegible]
[illegible]	**319,785**	[illegible]
	1,520,281	[illegible]

[illegible]

4. OTHER INCOME

	2023 ***RMB'000***	[illegible] *RMB'000*
[illegible]	**61,239**	[illegible]
[illegible]	**203**	[illegible]
[illegible]	**463,538**	[illegible]
[illegible]	**—**	[illegible]
	524,980	[illegible]

5. PROFIT BEFORE TAX

[illegible]

	2023 *RMB'000*	[illegible] *RMB'000*
[illegible]	16,189,857	[illegible]
[illegible]	5,405,452	[illegible]
[illegible]		
[illegible]	9,322,174	[illegible]
[illegible]	553,831	[illegible]
[illegible]	328,098	[illegible]
[illegible]	35,898	[illegible]
	10,240,001	[illegible]
[illegible]		
[illegible]	3,877,623	[illegible]
[illegible]	(56,687)	[illegible]
	3,820,936	[illegible]
[illegible]	4,660	[illegible]
[illegible]	1,517,737	[illegible]
[illegible]	1,282,683	[illegible]
[illegible]	2,408	[illegible]
[illegible]	121,339	[illegible]
[illegible]	131,927	[illegible]
[illegible]	—	[illegible]
[illegible]	21,592	[illegible]
[illegible]	61,284	—
[illegible]	13,119	—
[illegible]	318,258	[illegible]
[illegible]	113,749	[illegible]
[illegible]	(558,489)	[illegible]
[illegible]	(47,204)	[illegible]
[illegible]	452,384	[illegible]
[illegible]	(710,599)	[illegible]
[illegible]	(13,027)	[illegible]
[illegible]	1,046	[illegible]
[illegible]	(538)	[illegible]
[illegible]	45,909	[illegible]

[illegible]

[illegible] “Phixen” [illegible]

	2023 *RMB’000*	[illegible] *RMB’000*
[illegible]	**529,206**	[illegible]
[illegible]	**(159,702)**	[illegible]
[illegible]	**369,504**	[illegible]

9. DIVIDENDS

Cash dividend

	2023 *RMB’000*	[illegible] *RMB’000*
[illegible]	**721,548**	[illegible]

[illegible]

[illegible]

10. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

[illegible]

[illegible]

	2023 *RMB'000*	[illegible] *RMB'000*
Earnings		
[illegible]	**2,398,606**	[illegible]
[illegible]	**(1,050)**	—
[illegible]	**2,397,556**	[illegible]
[illegible]	**1,050**	—
[illegible]	**2,398,606**	[illegible]

	Number of shares **2023**	[illegible]
Shares		
[illegible]	**2,669,655,211**	[illegible]
[illegible]	**253,150**	[illegible]
	2,669,908,361*	[illegible]

[illegible]

11. TRADE AND BILLS RECEIVABLES

	2023 *RMB'000*	[illegible] *RMB'000*
[illegible]	**7,643,737**	[illegible]
[illegible]	**24,492**	[illegible]
	7,668,229	[illegible]

[illegible]

[illegible]

	2023 *RMB'000*	[illegible] *RMB'000*
[illegible]	**7,436,979**	[illegible]
[illegible]	**333,408**	[illegible]
[illegible]	**77,594**	[illegible]
[illegible]	**64,952**	[illegible]
	7,912,933	[illegible]
[illegible]	**(269,196)**	[illegible]
	7,643,737	[illegible]

12. TRADE AND BILLS PAYABLES

	2023 *RMB'000*	[illegible] *RMB'000*
[illegible]	**5,507,366**	[illegible]
[illegible]	**652,253**	[illegible]
	6,159,619	[illegible]

[illegible]

	2023	[illegible]
	RMB'000	*RMB'000*
[illegible]	**5,191,820**	[illegible]
[illegible]	**223,314**	[illegible]
[illegible]	**57,124**	[illegible]
[illegible]	**35,108**	[illegible]
	5,507,366	[illegible]

13. EVENTS AFTER THE REPORTING PERIOD

[illegible]

MANAGEMENT DISCUSSION AND ANALYSIS

THE BOARD'S DISCUSSION AND ANALYSIS ON OPERATIONS OF THE GROUP FOR THE REPORTING PERIOD

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

	2023 revenue Amount	Percentage of revenue (%)	[illegible]	[illegible] (%)	[illegible] (%)
By business segment					
[illegible][N 1]	**30,080**	**72.92**	[illegible]	[illegible]	[illegible]
[illegible][N 2]	**4,386**	**10.63**	[illegible]	[illegible]	[illegible]
[illegible]	**6,667**	**16.16**	[illegible]	[illegible]	[illegible]
By geographical locations					
[illegible]	**30,878**	**74.86**	[illegible]	[illegible]	[illegible]
[illegible]	**10,371**	**25.14**	[illegible]	[illegible]	[illegible][N 3]

N 1: [illegible]

N 2: [illegible]

N 3: [illegible]

I. MAIN OPERATIONAL PROGRESS OF THE GROUP DURING THE REPORTING PERIOD

1. Continued to promote the innovation transformation and the development and launch of innovative products

[illegible]

2. Continued to enhance global operation capabilities

[illegible]

[illegible]

[illegible]

- ***I e a a a e a e d c***

[illegible]

[illegible]

- ***P e ba -a ce ec e a***

[illegible]

- ***P e b d d c e e a a a a da d***

[illegible]

3. Continued to strengthen business focus by product lines and enhance efficiency through integration

[illegible]

[illegible]

[illegible]

4. Matured commercialization system

[illegible]

[illegible]

5. Digitally empowered business continued to grow

[illegible]

[illegible]



Progress during the Reporting Period	Drug name/code	Target/mechanism	Drug Category	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks
	[illegible]	[illegible]	[illegible]	[illegible]						[illegible]
	[illegible]	[illegible]	[illegible]	[illegible]						—

[illegible]

N 1: [illegible]

N 2: [illegible]

N 3: [illegible]

N 4: [illegible]

N 5: [illegible]

Table 2: Major marketed innovative products and description of core categories

No.	Therapeutic area	Product name	Description of product	Photo of product
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	

No.	Therapeutic area	Product name	Description of product	Photo of product
[illegible]	[illegible]	[illegible]	[illegible]	马来酸阿伐曲泊帕片 Doptelet
[illegible]		[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	

No.	Therapeutic area	Product name	Description of product	Photo of product
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	

No.	Therapeutic area	Product name	Description of product	Photo of product
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	

No.	Therapeutic area	Product name	Description of product	Photo of product
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]	[illegible]	[illegible]	[illegible]	
[illegible]		[illegible]	[illegible]	100mg 沙库巴曲缬沙坦钠片 Sacubitril Valsartan Sodium Tablets

* [illegible]

II. SEGMENT PERFORMANCE OVERVIEW

1. Pharmaceutical manufacturing

***Performance* [illegible]**

[illegible]

[illegible] ① [illegible]

[illegible]

Major therapeutic area	2023	[illegible]	[illegible] (%)
[illegible] (N 1, 5)	**7,638**	[illegible]	[illegible]
[illegible] (N 2, 5)	**4,340**	[illegible]	[illegible]
[illegible] (N 5)	**2,824**	[illegible]	[illegible]
[illegible] (N 3, 5)	**1,677**	[illegible]	[illegible]
[illegible] (N 4, 5)	**1,184**	[illegible]	[illegible]
[illegible] (N 5)	**1,271**	[illegible]	[illegible]

N 1: [illegible]

N 2: [illegible]

N 3: [illegible]

N 4: [illegible]

N 5: [illegible]

[illegible]

[illegible]

[illegible]

[illegible] 一
心坦 [illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Sales during the Reporting Period	Number	Preparation varieties or series
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]

I a e e

- T K r r [illegible] K (PD-1 r) [illegible] r K r r r [illegible] r

[illegible]

[illegible]

[illegible]

- *A r r K - K r CAR-T K r r K r r r*

[illegible]

[illegible]

[illegible]

- *Pr [illegible] r [illegible] r [illegible] r K*

[illegible]

[illegible]

[illegible]

[illegible]《藥品生產許可證》[illegible]《藥品經營許可證》[illegible]

[illegible]力妥寧[illegible]

- *Pr r r 2023 N M K I r K Dr C*

R&D a

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese mainland as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	—
[illegible]		[illegible]	[illegible]	[illegible]	—
[illegible]		[illegible]	[illegible]	[illegible]	—
[illegible]		[illegible]	[illegible]	[illegible]	—
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	—	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	—

[illegible]

Table 5 — License-in innovative drugs

No.	Therapeutic area	Drug name/code	Indications	R&D progress in major licensed territory as at the end of the Reporting Period
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]			[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]			[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

No.	Therapeutic area	Drug name/code	Indications	R&D progress in major licensed territory as at the end of the Reporting Period
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]			[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]

N 1: [illegible]

N 2: [illegible]

Table 6 — Biosimilars under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese mainland as at the end of the Reporting Period
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
			[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

[illegible]

[illegible]

Table 7 — Products won tenders for centralized procurement

No.	Round selected	Name of drugs	Indications	Specifications	Charge unit
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]

No.	Round selected	Name of drugs	Indications	Specifications	Charge unit
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

2. Medical Devices and Medical Diagnosis

[illegible] ① [illegible] ② [illegible]

Medical Device

[illegible]

[illegible]

[illegible]

[illegible] “Ion System” [illegible]

[illegible]

Medical Data

[illegible]

4. Pharmaceutical Distribution and Retail

[illegible]

[illegible]

[illegible]

[illegible]

5. Financing

[illegible]

[illegible]

III. CORE COMPETENCE ANALYSIS

[illegible]

[illegible]

[illegible]

IV. MAJOR OPERATIONS IN THE REPORTING PERIOD

(I) Analysis on Principal Operations

1. *A a C a e Ree a I e I c eSae e adSae e Ca F*

[illegible]

Items	Amount for the year	Amount for last year	Year-on-year change	*R*
[illegible]	[illegible]	[illegible]	[illegible]	*N 1*
[illegible]	[illegible]	[illegible]	[illegible]	*N 1*
[illegible]	[illegible]	[illegible]	[illegible]	*N 2*
[illegible]	[illegible]	[illegible]	[illegible]	*N 3*
[illegible]	[illegible]	[illegible]	[illegible]	*N 4*
[illegible]	[illegible]	[illegible]	[illegible]	*N 5*
[illegible]	[illegible]	[illegible]	[illegible]	*N 5*
[illegible]	[illegible]	[illegible]	[illegible]	*N 6*
[illegible]	[illegible]	[illegible]	[illegible]	*N 7*

N 1: [illegible]

N 2: [illegible]

N 3: [illegible]

N 4: [illegible]

N 5: [illegible]

N 6: [illegible]

N 7: [illegible]

2. A a Re e e a d C Sa e

Pr K O r S , Pr K , G r K L K

[illegible]

Principal Operations by Segments

By segments	Revenue	Cost of sales	Gross profit margin (%)	Year-on-year change in revenue (%)	Year-on-year change in cost of sales (%)	Year-on-year change in gross margin
[illegible]	[illegible]	[illegible]	[illegible]	–		

Principal Operations by Products

By products	Revenue	Cost of sales	Gross profit margin (%)	Year-on-year change in revenue (%)	Year-on-year change in cost of sales (%)	Year-on-year change in gross margin
[illegible] (N 2)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 3)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Principal Operations by Geographical Locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Year-on-year change in revenue (%)	Year-on-year change in cost of sales (%)	Year-on-year change in gross margin
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 4)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

N 1: [illegible]

N 2: [illegible]

N 3: [illegible]

N 4: [illegible]

[illegible] A [illegible] Pr [illegible] K [illegible]

Major products	Unit	Production volume	Sales volume	Inventory	Year-on-year change in production volume (%)	Year-on-year change in sales volume (%)	Year-on-year change in inventory (%)
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

N : [illegible]

[illegible]

By Segments

By Segments	Cost	Amount for the period	Percentage of the total cost for the period (%)	Amount for the corresponding period of last year	Percentage of the total cost for the corresponding period of last year (%)	Ratio of change for the period as compared with the corresponding period of last year (%)
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 1)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

[illegible]

By Products

By Products	Cost	Amount for the period	Percentage of the total cost for the period (%)	Amount for the corresponding period of last year	Percentage of the total cost for the corresponding period of last year (%)	Ratio of change for the period as compared with the corresponding period of last year (%)
[illegible] (N 2)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 3)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 4)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

N 1: [illegible]

N 2: [illegible]

N 3: [illegible]

N 4: [illegible]

M r C r S r

[illegible]

[illegible]

3. *E e e*

[illegible]

[illegible]

4. *R&D E e d e*

AKK r R&D r

藥品註冊管理辦法

R&D Expenditures

D K

[illegible]

5. *Ca F*

[illegible]

Items	Amount for the period	Amount for the corresponding period of last year	Ratio of change *(%)*	Reasons
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

(II) Assets and liabilities analysis

[illegible]

Assets and liabilities

[illegible]

Items	Amount as at the end of the period	Percentage of the amount as at the end of the period to the total asset *(%)*	Amount as at the end of last period	Percentage of the amount as at the end of last period to the total assets *(%)*	Ratio of change for the amount as at the end of the period as compared with the amount as at the end of last period *(%)*	Reasons
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	—	—	[illegible]	[illegible]
[illegible]	—	—	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

N 1: [illegible]

N 2: [illegible]

N 3: [illegible]

N 4: [illegible]

N 5: [illegible]

N 6: [illegible]

N 7: [illegible]

N 8: [illegible]

N 9: [illegible]

N 10: [illegible]

(III) Analysis on Subsidiaries and Investees

[illegible]

[illegible]

[illegible]

Name of subsidiary	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 1)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible] (N 2)	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

N : [illegible]

N 1: [illegible]

N 2: [illegible]

[illegible]

[illegible]

Name of subsidiary	Major business	Registered capital	Total assets	Net assets	Revenue	Net profit

[illegible] 10% [illegible]

[illegible]

Name of company	Principal activities	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

[illegible]

[illegible]

[illegible]

Name	Acquired through	Date of acquisition/merger

[illegible]

Name	Disposed through	Date of disposal
[illegible]	[illegible]	[illegible]

N : [illegible]

(IV) Employees and Remuneration Policies

[illegible]

THE BOARD'S DISCUSSION AND ANALYSIS ON FUTURE DEVELOPMENT OF THE GROUP

I. Industry Landscape and Trends

[illegible]

[illegible]

II. Corporate Development Strategies

[illegible]

III. Operation Plan

[illegible]

[illegible]

P a ace ca Ma ac

[illegible]

[illegible]

[illegible]

[illegible]

Med ca De ce a d Med ca D a

[illegible]

[illegible]

Hea ca e Se ce

[illegible]

P a ace ca D b a d Re a

[illegible]

F a c

[illegible]

IV. Potential Risks

(I) Industry policies adjustments

[illegible]

[illegible]

[illegible]

[illegible]

(II) Market risks

[illegible]

[illegible]

(III)Business and operating risks

R&D r r

[illegible]

[illegible]

C r r r K/ r K

[illegible]

[illegible]

(IV) Management risks

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

(V) Foreign exchange risks

[illegible]

[illegible]

(VI) Force majeure risks

[illegible]

[illegible]

OTHER EVENTS

I. Approval for Registration of Corporate Bonds by the CSRC

[illegible] "**Approval**" [illegible]

III. Increase in Shareholding by a Controlling Shareholder

[illegible] **“Shareholding Increase Plan”** [illegible]

[illegible]

IV. 2022 Restricted A Share Incentive Scheme

[illegible]

[illegible]

V. 2022 H Share Employee Share Ownership Scheme

[illegible]

[illegible]

REPURCHASE, SALE OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES

2022 Restricted A Share Incentive Scheme

[illegible]

[illegible]

Sell back of “21 Fosun 01” Corporate Bonds

[illegible] “[illegible]” “[illegible]復藥[illegible]” [illegible] ”《上海復星醫藥(集團)股份有[illegible]公司[illegible]年公開發行公司債券(第一期)募集説明書(面向專業投[illegible]者)》 [illegible]

[illegible]

COMPLIANCE WITH THE CG CODE

[illegible]

[illegible]

PUBLICATION OF ANNUAL RESULTS AND ANNUAL REPORT

[illegible]

DEFINITIONS

[illegible]

[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible] 錦州奧鴻藥業有 [illegible] 任公司 [illegible]
[illegible]	[illegible]

美中互利北京國 易有 公司

上海復星醫藥 集團股份有 公司

中國證券監督管理委員會

佛山復星禪誠醫 有 公司

[illegible]	[illegible] 復星 立峰 大連 生□製藥有 公司 [illegible]
[illegible]	[illegible] 復星安□金 成都 生□製藥有 公司 [illegible]
[illegible]	[illegible] 上海復星高科技 集團 有 公司 [illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible] 復星凱□生□科技有 公司 [illegible]
[illegible]	[illegible] 上海復拓知達醫療科技有 公司 [illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible] 廣州新市醫 有 公司 [illegible]
[illegible]	[illegible] 桂林南藥股份有 公司 [illegible]
[illegible]	[illegible]
[illegible]	[illegible]

[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible] 湖南洞庭藥業股份有 公司 [illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible] 直觀復星醫療□械技術(上海)有 公司 [illegible]
[illegible]	[illegible] □醫療投□管理有 公司 [illegible] 國藥控股醫療投□管理有 公司 [illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible] 《國家基 醫療保 、工 保 和生育保 藥品目錄》

中國國家藥品監督管理局

上海復宏漢霖生□技術股份有 公司

上海證券交易所

上海星晨兒童醫 有 公司

上海曜康醫藥科技有 公司

重慶星 整形 科醫 有 □任公司

"[illegible]"	[illegible] 國藥控股股份有　公司 [illegible]
"[illegible]"	[illegible] 國藥產業投□有　公司 [illegible]
"[illegible]"	[illegible]
"[illegible]"	[illegible]
"[illegible]"	[illegible]
"[illegible]"	[illegible]
"[illegible]"	[illegible]
"[illegible]"	[illegible]
"[illegible]"	[illegible] 江蘇萬邦生化醫藥集團有　□任公司 [illegible]
"[illegible]"	[illegible]
"[illegible]"	[illegible]
"[illegible]"	[illegible]《上海復星醫藥（集團）股份有　公司董事／有關　員進行證券交易的書面守則》
"[illegible]"	[illegible] 江蘇星諾醫藥科技有　公司 [illegible]
"[illegible]"	[illegible] 廣州市心怡堂大藥房有　公司 [illegible]
"[illegible]"	[illegible] 徐州萬邦　藥房連鎖有　公司 [illegible]
"[illegible]"	[illegible] 徐州星晨婦兒醫　有　公司 [illegible]

“ ”

“ ”

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
C

A , K r K r C r Mr. W , Mr. W K ,
M . G Mr. W D ; - K r K r C r Mr. C Q , Mr. F ,
Mr. Mr. P D ; - K r K r C r M . L L ,
Mr. T G , Mr. W Q Mr. T S H .

F r K r